Motley Fool Australia

Why this ASX medical technology share is pushing higher today

Doctor with stethoscope in hand and data graph showing upward trend
Image Source: Getty Images

The Next Science Ltd (ASX: NXS) share price has managed to avoid the market selloff and push higher on Friday.

In afternoon trade the medical technology company’s shares are up 1% to $1.86.

What is Next Science?

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, United States.

Its primary focus is on the development and commercialisation of its proprietary Xbio technology to reduce the impact of biofilm based infections in human health.

Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria.

Why is the Next Science share price pushing higher?

Investors have been buying the company’s shares on Friday following the release of its full year results.

For the 12 months ended December 31, Next Science delivered a 43% increase in revenue to US$4.1 million and a 42% lift in gross profit to US$3.5 million. This was achieved despite the company facing challenges due to delays with its distribution partners in the United States, and with delayed regulatory approvals in Europe.

Also improving during the 12 months was its underlying EBITDA. Next Science posted an EBITDA loss of US$11.1 million, compared to a loss of US$13.1 million in FY 2018. This was the result of a 6% reduction in operating expenses, thanks largely to a sharp reduction in employee expenses following a sales and marketing restructure.

At the end of the period the company had cash of US$16.9 million. Management believes this is sufficient to fund its business plan and grow its investments.

Outlook.

No guidance was provided, but management revealed that it is focused on growing the sales of its existing products in FY 2020.

It will be working with its partners on geographic market expansion when appropriate regulatory approvals are cleared, as well as the launch of BlastX with the 3M KCI sales force.

Outside this, the on-boarding of new partners and new product launches are expected to also boost its sales in FY 2020.

Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

*Returns as of 6/8/2020

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Related Articles...